应用寡聚核苷酸检测c-Ha-ras癌基因点突变

人工合成的寡聚核苷酸探针能够准确地检测出克隆的c-Ha-ras癌基因第12位密码子是否发生点突变。将多聚酶DNA链延伸反应(PCR)与寡聚核苷酸探针结合起来测定组织或细胞株中的单拷贝基因c-Ha-ras第12位密码子的点突变,获得满意的结果。此方法的建立,有助于肿瘤的早期诊断、分型等方面的研究。     

PCR-RFLP 方法测定 ras 癌基因点突变

曾使用 PCR-RFLP 方法分析过 c-Ha-ras 癌基因第12密码子的点突变.因N-ras 基因第12位密码子、K-ras 基因第12和13位密码子无已知的限制性内切酶的酶切位点,不能使用 PCR-RFLP 方法分析这些位点的突变.在 PCR 引物的3′端引入一个误配的碱基使之正好成为某限制性内切酶的酶切位点,这样便能使用PCR-RFLP 技术分析 c-Ha-ras 基因第61位、N-ras 基因第12位、K-ras 基因第12和13位密码子的点突变.     

宫颈癌c-Ha-ras癌基因点突变的研究

用聚合酶链反应放大技术扩增宫颈癌e-Ha-ras癌基因第一外显子的基因片段,反应终产物与5′末端标记的特异寡核苷酸探针杂交,在18例宫颈癌DNA样品中,发现有6例存在e-Ha-ras癌基因第12位密码子的G-T突变,突变率为33％。推测第12位密码子的点突变是宫颈癌Ha-ras基因的活化途径之一。     

错配碱基PCR-RFLP检测K-ras癌基因点突变

错配碱基套式PCR-RFLP检测K-ras癌基因第12位密码子点突变,并与一步法PCR-RFLP作比较.结果显示套式PCR-RFLP可检测出500细胞中的一个突变细胞,比一步法PCR-RFLP分析的敏感性提高了100倍.利用该方法检测纤维支气管镜收集的标本中的突变细胞,结果发现9例肺腺癌中有5例发生了K-ras癌基因第12位密码子点突变.提示该方法可行,值得推广应用.     

胃癌和癌旁组织癌基因c-Ha-ras第12位密码点突变测定的研究

 <正> 胃癌是我国发病率、死亡率最高的肿瘤之一,癌基因c-Ha-ras第12位密码子的点突变(鸟嘌呤突变为胸腺嘧啶)是其激活的重要方式之一,这一突变使c-Ha-ras的产物p21蛋白第12位氨基酸从正常的甘氨酸变为胃癌中的缬氨酸~[1-4]。点突变的测定可成为临床医生判断术后患者预后的有用指标,为拟定更有效的治疗方案提供帮助。据有关资料统计,点突变阳性及阴性患者的术后生存期分别为11.3±4.5个月和>29±8.1个月,两组间有显著差异     

MGMT基因启动子甲基化与膀胱尿路上皮癌生物学行为关系的研究

目的 检测膀胱尿路上皮癌组织中O^6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）基因启动子甲基化状态,探讨MGMT甲基化与其蛋白表达水平以及肿瘤生物学行为之间的关系.方法 应用免疫组织化学SP法和甲基化特异性PCR（MSP）分别检测60例膀胱尿路上皮癌及15例正常膀胱黏膜组织中MGMT蛋白表达情况和MGMT基因启动子甲基化状态.结果 膀胱癌组织中MGMT蛋白阳性表达率为35.0 %（21/60）,低于正常膀胱组织（86.7 %,13/15,P〈0.01）.膀胱癌组织中MGMT甲基化阳性率为45.0 %（27/60）,明显高于正常膀胱组织（0.0 %,0/15,P〈0.01）;MGMT启动子甲基化与其蛋白表达呈负相关（r = -0.453,P〈0.01）;并且高级别膀胱癌中MGMT甲基化阳性率（70.6 %,12/17）要比低级别膀胱癌高（34.9 %,15/43）,（P〈0.05）,而MGMT甲基化与膀胱癌临床分期无明显关系.结论 MGMT启动子甲基化可能参与了膀胱尿路上皮癌的发生和肿瘤分化,MGMT启动子甲基化有望成为预判膀胱癌预后的重要标记.     

Clusterin和p21在膀胱癌中的表达及临床意义

目的:研究Clusterin和p21基因在膀胱癌中的表达和临床意义及二者的相关性.方法:采用免疫组织化学检测20例正常膀胱组织(NB)、60例膀胱癌组织(BTCC)中Clusterin和p21蛋白的表达情况,根据染色强度和阳性细胞数作半定量分析.结果:Clus-terin、p21蛋白在膀胱癌中的阳性表达率明显高于正常膀胱组织,阳性表达率分别为70.0%、63.3%;20.0%、15.0%(P<0.05);二者在低分化、浸润性肿瘤的阳性表达率明显高于高分化、浅表性肿瘤(P<0.05),Clusterin和p21在膀胱癌中的表达存在正性相关(P<0.05).结论:Clusterin、p21蛋白的表达与膀胱癌病理组织学分级、临床分期相关,二者联合检测可为膀胱癌的诊断及预后提供一定参考价值.     

K-ras基因突变及表达与胰腺癌的关系

目的:探讨K-ras基因突变及蛋白表达对胰腺癌的诊断价值。方法:采用突变等位基因特异性扩增(PCR-MASA)检测31例胰腺癌和22例非胰腺癌石蜡包埋组织中K-ras基因12密码子点突变情况,并通过免疫组化法检测其K-ras蛋白的表达。结果:胰腺癌患者K-ras基因12密码子点突变率为80.6%(25/31),K-ras蛋白表达阳性率为87.1%(27/31);而非胰腺癌患者K-ras基因12密码子点突变率为27.3%(6/22),K-ras蛋白表达阳性率31.8%(7/22)。胰腺癌患者K-ras基因突变率及K-ras蛋白表达阳性率均明显高于非胰腺癌患者(P均0.05)。K-ras基因突变与其蛋白表达呈正相关(r=0.542,P0.05),而与胰腺癌患者的性别、年龄、肿瘤部位、肿瘤大小、临床分期及分化程度等临床病理特征均无显著相关性(P均0.05)。结论:胰腺癌K-ras基因突变的发生率升高,且K-ras蛋白表达异常上调,二者可能有助于胰腺癌的诊断。     

一种测定癌基因c-Ha-ras点突变的简易方法——PCR-RFLP法

利用多聚酶DNA链延伸反应与限制性内切酶酶解片段长度多态性分析相结合,可简单、迅速、准确地对胃癌组织及细胞株DNA中癌基因c-Ha-ras第12位密码子是否存在点突变进行测定。这个方法是使用非同位素方法对单拷贝基因点突变进行检测的首次报道。     

PCR-特异探针杂交检测肿瘤组织 Ki-ras 基因点突变

用福尔马林固定-石腊包埋的人肿瘤组织切片,经脱腊处理直接用 PCR(poly-merase chain reaction)技术扩增 Ki-ras 癌基因序列中包括12,13位密码子的 DNA片段,并分别以5种含特异突变点的寡核苷酸探针代替3′端引物,经 PCR 扩增的产物作为点突变的阳性对照.用上述五种探针进行选择性斑点杂交,检测了人肺癌及结直肠癌组织的 Ki-ras 基因12及13位点突变.为了封闭杂交时的非特异结合,采用野生型冷探针与标记的含突变点的探针同时进行杂交的方法,有效地消除了杂交过程中可能产生的假阳性,而不影响真阳性反应的出现.因而增加了检测的可靠性.     

A method to quantitatively detect H-ras point mutation based on electrochemiluminescence

Conventional methods for point mutation detection are usually multi-stage, laborious, and need to use radioactive isotopes or other hazardous materials, and the assay results are often semi-quantitative. In this work, a protocol for quantitative detection of H-ras point mutation was developed. Electrochemiluminescence (ECL) assay was coupled with restriction endonuclease digestion directly from PCR products. Only the wild-type amplicon containing the endonuclease's recognition site can be cut off, and thus cannot be detected by ECL assay. Using the PCR-ECL method, 30 bladder cancer samples were analyzed for possible point mutation at codon 12 of H-ras oncogene. The results show that the detection limit for H-ras amplicon is 100 fmol and the linear range is more than three orders of magnitude. The point mutation was found in 14 (46.7%) out of 30 bladder cancer samples. The experiment results demonstrate that the PCR-ECL method is a feasible quantitative approach for point mutation detection due to its safety, high sensitivity, and simplicity.     

膀胱尿路上皮癌组织CRMP2、NUSAP1、hMSH2表达与临床病理参数和预后的关系研究

目的:探讨膀胱尿路上皮癌组织坍塌反应调节蛋白2(CRMP2)、核仁和纺锤体相关蛋白l(NUSAP1)、人类错配修复基因2(h MSH2)表达与临床病理参数和预后的关系。方法:选取2018年2月至2020年3月我院收治的85例膀胱尿路上皮癌患者,比较手术切除的癌组织和癌旁粘膜组织中CRMP2、NUSAP1、hMSH2表达情况。比较不同病理参数癌组织中CRMP2、NUSAP1、hMSH2阳性表达率差异,分析CRMP2、NUSAP1、hMSH2与膀胱尿路上皮癌患者预后的关系。结果:与癌旁组织比较,膀胱尿路上皮癌患者癌组织中CRMP2、NUSAP1阳性表达率增高(P<0.05),hMSH2降低(P<0.05)。T2-T4、高级别肿瘤患者癌组织中CRMP2、NUSAP1阳性表达率高于Tis-T1、低级别肿瘤患者(P<0.05),多发癌组织中CRMP2阳性表达率高于单发(P<0.05),T2-T4癌组织中hMSH2阳性表达率低于Tis-T1(P<0.05)。总生存率、无复发生存率、无进展生存率比较,CRMP2阳性表达者低于CRMP2阴性表达者(P<0.05),hMSH2阴性表达者低于hMSH2阳性表达者(P<0.05),NUSAP1阳性表达者无复发生存率、无进展生存率低于NUSAP1阴性表达者(P<0.05)。Cox风险比例回归分析结果显示复发、进展、CRMP2阳性表达、NUSAP1阳性表达、hMSH2阴性表达是膀胱尿路上皮癌患者不良预后的危险因素(P<0.05)。结论:CRMP2、NUSAP1阳性表达,hMSH2阴性表达与膀胱尿路上皮癌临床病理参数、复发转移以及不良预后有关。     

Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell lines

The epidermal growth factor (EGF) receptor has been suggested to have an important role in tumor initiation and progression of human bladder cancers. Grb2 protein, which is the downstream effector of the EGF receptor, acts as an adaptor protein between the EGF receptor and the Ras guanine-nucleotide exchange factor, son of sevenless (Sos) protein. Sos protein regulates the action of Ras protein by promoting the exchange of GDP for GTP. However, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer. The aim of the present study is to clarify the significance of these proteins in human bladder cancer cell lines. In the present study, we used four human bladder cancer cell lines (T24, KU-7, UMUC-2, UMUC-6) and two kinds of cultured normal urothelial cells (HMKU-1, HMKU-2) isolated from patients with no malignancy. We examined the expression of EGF receptor, Grb2, and Sos proteins in these cells by Western blot analysis. Furthermore, the bladder cancer cell lines were subjected to sequence analysis to identify a point mutation in the c-H-ras gene at codon 12. There was no marked difference in the expression of the EGF receptor between human bladder cancer cell lines and cultured normal urothelial cells. On the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not. These results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.     

Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.

Ras oncogenes are thought to play a critical role in cellular proliferation and tumorigenesis. Reversal of the malignant phenotype, inhibition of tumor growth, and decreased tumorgenicity have been demonstrated with the use of anti-H-ras ribozymes. In this study, the therapeutic efficacy of a hammerhead ribozyme targeting the mutated H-ras oncogene was investigated in an experimental bladder cancer model using a recombinant adenovirus as delivery vehicle. Tumors were established in nude mice by subcutaneous injection of EJ human bladder carcinoma cells harboring a point mutation of the H-ras gene. The tumors were treated with intralesional injections of an adenovirus expressing an anti-H-ras ribozyme (rAd-Hras Rz) by different schedules at serial titers, and the tumor inhibition efficacy was analyzed. The viral infection efficacy and kinetics of ribozyme expression were also evaluated. Intralesional injection of rAd-Hras Rz resulted in significant antineoplastic effects in a dose-dependent fashion. Complete regression of the tumor was achieved by rAd-Hras Rz in several cases without recurrence during the 50-day observation period. Although there was moderate vector-associated cytotoxicity in this cell line, complete regressions were not observed in the cases treated with control adenovirus vectors or vectors expressing an inactive anti-H-ras ribozyme or anti-H-ras antisense oligonucleotides. These results suggest the efficacy of a ribozyme-encoding adenovirus in the experimental gene therapy of human bladder cancer.     

Heterologous expression and characterization of the human R-ras gene product.

We directly expressed human R-ras 23,000-dalton protein (p23) cDNA in Escherichia coli under the control of the trp promoter. GTP-dependent phosphorylation of a p23 threonine 85 substitution mutant was observed. This result is in direct analogy to the autokinase activity of H-ras and K-ras threonine 59 substitution mutants. Normal p23 protein was detected in the human fibrosarcoma cell line HT1080 by immunoprecipitation with rabbit antibodies raised against an E. coli-expressed R-ras fusion protein. The R-ras p23 protein was found to be 3H labeled in the presence of [9,10(n)-3H]palmitic acid and is associated with the P100 membrane fraction of HT1080 cells. These data suggest that human R-ras p23 has biochemical properties very similar to those of the p21 products of the H-, K-, and N-ras proto-oncogenes. We constructed an R-ras minigene and engineered the expression of normal and mutant alleles from the simian virus 40 early region promoter. Normal and mutant R-ras gene products were authenticated by transient expression in COS-7 cells and immunoprecipitation. The valine 38-substituted R-ras p23 displayed reduced electrophoretic mobility. R-ras p21-like proteins, made by eliminating the first 26 R-ras codons, displayed evident mobility differences between the pro form and mature form, along with a valine 12 substitution-dependent change in electrophoretic mobility. Rat-1 fibroblasts were transfected with normal and mutant R-ras alleles and normal and activated H-ras alleles. Unlike the human T24 bladder oncogene-encoded p21, mutant R-ras alleles do not cause monolayer focus formation or growth in soft agar of rat fibroblasts.     

Genetic analysis of H-ras intron-1 polymorphic and variable tandem repeat regions in human breast cancer

H-ras is a member of the ras superfamily of genes. This gene encodes for a 21 kDa protein (p21) which is located on the inner surface of the plasma membrane. Ras genes are involved in a wide variety of human tumors, and there is a known correlation between H-ras activation and breast carcinogenesis. H-ras contains a polymorphic region, a repeated hexanucleotide -GGGCCT - located in intron 1 close to the 5' of the gene (HRM region). Three alleles of this region, P1, P2 and P3, have been identified that contain two, three and four repeats of the hexanucleotide, respectively. H-ras possesses a minisatellite DNA of the variable tandem repeat (VTR) which is located 1000 bp downstream of the gene displaying linkage disequilibrium with HRM. The purpose of this study was to estimate the frequency of P1, P2 and P3 in the normal population and in patients with breast cancer. We studied 56 biopsy specimens from patients with breast cancer, 61 normal blood samples, and 30 pairs of normal and tumoral breast tissues for VTR analysis. There was a difference in the distribution of P1, P2 and P3 alleles between normal and breast cancer samples. The frequency of P1 homozygosity was shown to be almost twice as high in women with breast cancer compared to healthy women (72% versus 39%). These results suggest that P1 homozygosity may be considered as a potential risk factor in breast carcinogenesis. In VTR analysis one sample presented a shift in mobility, but no polymorphism in the BstN I pattern of the 28 bp repetition core was observed.     

Ras oncogene mutations in urine sediments of patients with bladder cancer

Early detection of bladder cancer is particularly important since it dramatically affects the survival rates. However, neither urinary cytology nor tumor markers that are currently used are sensitive enough for the early detection of bladder cancer or recurrent disease. The ras genes are frequently mutated in cancer. In this study, we investigated the diagnostic potential of ras mutation analysis in urinary sediments of patients with bladder cancer using a single-strand conformation polymorphism analysis and polymerase chain reaction. Mutation in codon 12 of the H-ras gene was observed in 39% of the patients. Our results indicate that this approach may significantly improve diagnostic sensitivity in detecting bladder tumors.     

Anti-oncogenic PTEN induces ovarian cancer cell senescence by targeting P21

Deletion and mutation of phosphatase and tensin homolog deleted on chromosome10 (PTEN) are closely associated with the occurrence of tumors. Tumor suppressor gene PTEN mutation plays an important role in the pathogenesis of ovarian cancer. However, it has been unclear whether it can regulate the senescence of ovarian cancer cells. We speculated that PTEN might inhibit the occurrence and development of ovarian cancer by promoting the expression of P21. We found that the expression of TRIM39 in human ovarian cancer was significantly diminished. In SKOV3 cells treated with naringin, the expression of TRIM39, which binds P21 and inhibits P21 degradation, was significantly elevated. Real-time polymerase chain reaction (PCR), Western blot, and immunofluorescence were used to detected the expression of PTEN, p21, and TRIM39, β-galactosidase Staining was used to detect cell senescence, Ki67 staining was used to observe cell proliferation, Trim39 interference or overexpression assay was used to detect its function. We speculated that PTEN might promote SKOV3 cell senescence by increasing TRIM39 expression and decreasing P21 degradation. Furthermore, by interfering with TRIM39 in SKOV3 cells, we found that the expression of P21 was downregulated, and the number of senescent SKOV3 cells decreased. With overexpression of TRIM39 in SKOV3 cells, the expression of P21 was upregulated, and the number of senescent SKOV3 cells increased. When naringin, a PTEN agonist, was added to SKOV3 cells in which TRIM39 protein was interfered with, the expression of P21 was significantly lower than that in the control group, and the number of senescent ovarian cancer cells was significantly diminished. Our results indicated that PTEN maintained the stability of P21 and decreased the degradation of P21 by increasing TRIM39 expression, thus promoting the senescence of SKOV3 cells, and PTEN maintained the stability of p21 and promoted the aging of SKOV3 cells might be a novel therapeutic target for ovarian cancer.